Molina Q2 Shows Stabilization, But No Clear Recovery Signal

What happened

Molina Healthcare reported second quarter 2026 GAAP diluted EPS of $1.19 and adjusted EPS of $1.51, with premium revenue declining to $10.244 billion from $10.868 billion a year earlier. While adjusted EPS appears consistent with guidance for at least $5.00 for the full year, the top-line drop reflects continued membership contraction and the lag of state capitation rates behind medical cost trend. The press release lacks key detail on Medicaid medical care ratio (MCR), which the prior quarter reported at 92.0%, leaving investors without evidence of sequential improvement in the rate-trend gap. With the Florida Children’s Medical Services Plan transition pending on October 1, 2026, and an amended credit agreement providing temporary covenant relief, the risk of a second earnings reset remains material. Until the 10-Q confirms a downtrend in Medicaid MCR and management can point to concrete off-cycle rate actions, the 'trough year' narrative remains unproven.

Implication

Molina's rate-repair thesis remains intact but unconfirmed. Investors should hold existing positions and wait for sequential Medicaid MCR improvement in the 10-Q, or until visible off-cycle rate adjustments close the funding gap. The attractive entry zone remains near $165, with risk of re-testing $150 if MCR fails to improve.

Thesis delta

The Q2 results do not alter the core thesis of a trough year awaiting rate repair, but the absence of explicit MCR improvement in the press release and continued revenue decline increase the probability of the bear case (30% chance, $150 value). The WAIT rating is maintained; conviction remains at 3.0 until the 10-Q provides clear evidence of sequential Medicaid MCR decline.